← Back to Search

Other

45 mg LY3857210 for Osteoarthritis (OA05 Trial)

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 8

Summary

This trial is testing a new medication called LY3857210 to see if it can help reduce pain in people with osteoarthritis. The study focuses on those who suffer from chronic pain due to this condition and aims to find out if this new treatment can provide relief.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 8 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)
Secondary study objectives
Change From Baseline for Worst Pain Intensity as Measured by NRS
Change From Baseline in Overall Improvement as Measured by Patient's Global Impression of Change
Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm)
+6 more

Side effects data

From 2023 Phase 2 trial • 131 Patients • NCT05620576
6%
Urinary tract infection
5%
Pain in extremity
5%
Headache
3%
Vulvovaginal candidiasis
3%
Neuropathy peripheral
2%
Dizziness
1%
Cellulitis
1%
Back pain
1%
Fall
1%
Subcutaneous abscess
100%
80%
60%
40%
20%
0%
Study treatment Arm
45 mg LY3857210
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 45 mg LY3857210Experimental Treatment1 Intervention
Participants received 45 milligram (mg) LY3857210 orally once daily for up to 8 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo orally once daily for up to 8 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3857210
2022
Completed Phase 2
~430

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,667 Previous Clinical Trials
3,228,330 Total Patients Enrolled
24 Trials studying Osteoarthritis
5,235 Patients Enrolled for Osteoarthritis
Study DirectorEli Lilly and Company
1,383 Previous Clinical Trials
425,994 Total Patients Enrolled
9 Trials studying Osteoarthritis
2,146 Patients Enrolled for Osteoarthritis
~50 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top